AR-H067637XX

AR-H067637XX is the primary pharmacologically active metabolite of the anticoagulant prodrug AZD0837. It is a potent, specific, and reversible direct thrombin inhibitor that exerts its anticoagulant effects by inhibiting thrombin activity, thereby interfering with the coagulation cascade. The drug has been studied primarily for the prevention of stroke and systemic embolic events in patients with nonvalvular atrial fibrillation. It demonstrates dose-dependent effects on coagulation biomarkers such as D-dimer and thrombin generation. Clinical pharmacology studies have focused on its pharmacokinetics, pharmacodynamics, and safety profile in patients at risk for thromboembolic stroke[1][3][4][5].